NXTHERA INC / BOSTON SCIENTIFIC CORPORATION / Acquisition / Private

Synopsis

Acquisition by Boston Scientific of NxThera, a developer of the Rezum® system, a minimally invasive treatment options for men with symptoms arising from of benign prostatic hyperplasia (BPH).

Principals

target

Nxthera

bidder

Boston Scientific Corporation

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

latham & watkins

HQ - New York, United States

legal advisors

bidder

5445

Deals

£ 3,505.44 B

Total Value